Clinical Trial Update: CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating CYP2C19 genotype-specific dosing with therapeutic drug monitoring to achieve therapeutic voriconazole levels in invasive aspergillosis/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fungal Infection
• Invasive Aspergillosis

Drugs mentioned

• VORICONAZOLE (Voriconazole)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Aspergillosis Invasive, Fungal Infection | Phase 4 | Status: COMPLETED